virus
smallest
among
selfrepl
organ
yet
etiolog
agent
mani
difficult
treat
diseas
human
popul
broad
type
human
infect
caus
virus
respiratori
infect
common
cold
influenza
digest
infect
viral
gastroenter
central
nervou
system
infect
viral
mening
viral
enceph
skin
mucos
infect
herp
measl
mump
smallpox
rubella
hepat
infect
hepat
b
c
e
blood
infect
acquir
immunodefici
syndrom
hemorrhag
fever
yellow
fever
ebola
hemorrhag
fever
virus
abund
divers
biolog
entiti
earth
reason
high
incid
viral
infect
addit
virus
etiolog
agent
develop
human
tumor
particularli
cervic
cancer
hepat
cancer
main
method
costeffect
strategi
prevent
viral
infect
vaccin
meant
prevent
outbreak
increas
immun
vaccin
prevent
sever
common
acut
viral
infect
polio
rubella
measl
mump
influenza
yellow
fever
enceph
rabi
smallpox
hepat
b
develop
centuri
avail
larg
scale
effort
develop
safe
effect
vaccin
virus
caus
chronic
infect
human
immunodefici
viru
hepat
c
viru
give
expect
result
mani
viral
infect
symptomat
treatment
indic
expect
immun
system
fight
viru
howev
highvirul
virus
caus
seriou
viral
infect
antivir
treatment
essenti
patient
surviv
although
great
effort
made
find
effect
medic
still
drug
truli
cure
viral
infect
moreov
due
abil
virus
undergo
rapid
mutat
mechan
involv
develop
resist
antivir
drug
activ
case
resist
toward
antivir
drug
becom
global
health
threat
intrins
need
identifi
new
scaffold
use
discov
innov
less
toxic
highli
activ
antivir
agent
nitrogencontain
heterocycl
wide
distribut
natur
essenti
veget
anim
metabol
found
nucleic
acid
vitamin
antibiot
alkaloid
etc
addit
nitrogencontain
heterocycl
import
target
medicin
chemistri
found
half
commerci
avail
drug
also
act
versatil
intermedi
synthesi
complex
product
exhibit
outstand
biolog
activ
nitrogencontain
heterocycl
compound
exhibit
better
biolog
activ
nonnitrogen
compound
current
approxim
drug
approv
use
treatment
nine
human
viral
infect
caus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
herp
simplex
viru
hsv
influenza
viru
human
cytomegaloviru
hcmv
varicellazost
viru
vzv
respiratori
syncyti
viru
rsv
human
papillomaviru
drug
eg
acyclovir
cidofovir
idoxuridin
nevirapin
pleconaril
ribavirin
etc
nitrogen
heterocycl
molecul
fivememb
aromat
system
three
heteroatom
symmetr
posit
ring
extens
studi
due
pharmacolog
profil
physicochem
pharmacokinet
properti
deriv
known
compound
signific
divers
biolog
activ
antibacteri
antifung
antitubercular
analges
antiinflammatori
antidepress
anxiolyt
kinesin
inhibitor
etc
ring
also
found
sever
medicin
acetazolamid
methazolamid
cefazolin
cefazedon
sulfamethizol
megazol
nucleu
provid
compound
high
lipophil
abil
form
mesoion
system
associ
discret
region
posit
neg
charg
distinct
featur
allow
mesoion
compound
effici
cross
cellular
membran
lead
good
oral
absorpt
bioavail
strong
uniqu
interact
biolog
molecul
eg
dna
protein
etc
thu
increas
potenti
deriv
exhibit
biolog
activ
thiadiazol
ring
bioisoster
pyrimidin
pyridazin
ring
pyrimidin
nucleu
commonli
found
natur
occur
compound
biochem
import
well
drug
eg
pyrimidin
nucleosid
nucleotid
nucleic
acid
antivir
drug
pyridazin
nucleu
compon
pharmacolog
activ
compound
thiadiazol
ring
also
act
bioisoster
thiazol
ring
therefor
thiadiazol
deriv
act
way
third
fourthgener
antibacteri
cephalosporin
addit
featur
highlight
high
potenti
ring
system
medicin
chemistri
mani
research
suppos
connect
biolog
potenti
strongli
aromat
charact
ring
well
presenc
toxophor
nc
linkag
group
furthermor
high
vivo
stabil
low
toxic
higher
organ
also
attribut
ring
addit
amin
deriv
also
studi
moieti
deriv
known
antitumor
antitrypanosom
uricogen
properti
deriv
current
synthes
mani
laboratori
previou
paper
describ
sever
exhibit
antibacteri
antifung
antitubercular
antiparasit
activ
purpos
paper
present
small
molecul
possess
moieti
shown
antivir
activ
million
peopl
infect
human
immunodefici
viru
hiv
retrovirida
famili
report
highest
incid
infect
subsaharan
africa
third
world
hiv
infect
coupl
tropic
diseas
malaria
tuberculosi
caus
high
level
mortal
due
sexual
transmiss
acquir
immunodefici
syndrom
aid
affect
mani
young
worker
therefor
diseas
social
impact
also
signific
econom
impact
region
past
two
half
decad
differ
organ
compound
develop
drug
candid
treatment
aid
target
one
stage
viru
life
cycl
absorpt
fusion
entri
uncoat
revers
transcript
integr
transcript
matur
revers
transcriptas
rt
essenti
enzym
convert
singlestrand
rna
viral
genom
doublestrand
dna
integr
host
dna
sinc
rt
key
enzym
life
cycl
rt
inhibitor
nucleosid
nonnucleosid
structur
current
use
aid
treatment
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
didanosin
zalcitabin
stavudin
lamivudin
abacavir
tenofovir
emtricitabin
interact
competit
catalyt
site
rt
nonnucleosid
revers
transcriptas
inhibitor
nnrti
delavirdin
efavirenz
alloster
interact
site
adjac
nrti
bind
site
nonnucleosid
inhibitor
bind
site
nnb
due
high
select
low
cytotox
nnrti
gain
increasingli
import
role
hiv
infect
therapi
five
drug
class
nnrti
approv
treatment
hiv
infect
nevirapin
delavirdin
efavirenz
first
gener
drug
etravirin
intel
tablet
janssen
therapeut
compani
rilpivirin
edur
tablet
janssen
therapeut
compani
nextgener
nnrti
doravirin
new
nnrti
develop
merck
compani
complet
two
studi
doravirin
demonstr
antiretrovir
activ
immunolog
effect
similar
efavirenz
significantli
fewer
central
nervou
system
advers
event
januari
us
food
drug
administr
fda
accept
review
two
new
drug
applic
nda
doravirin
oncedaili
tablet
combin
antiretrovir
agent
oncedaili
fixeddos
combin
singl
tablet
doravirin
lamivudin
tenofovir
disoproxil
fumar
august
fda
approv
applic
doravirin
aid
treatment
pifeltro
tablet
doravirin
mg
delstrigo
tablet
doravirin
mg
lamivudin
mg
tenofovir
disoproxil
fumar
mg
sever
nnrti
eg
fosdevirin
lersivirin
underw
clinic
develop
program
discontinu
due
unfavor
pharmacokinet
efficaci
andor
safeti
factor
approxim
million
patient
access
antiretrovir
therapi
capabl
control
viremia
reduc
mortal
howev
longterm
treatment
antiretrovir
agent
lead
drug
resist
due
rapid
mutat
viral
genom
result
rt
mutat
hiv
chemotherapi
failur
concern
attract
particular
focu
research
new
antiretrovir
drug
address
limit
current
avail
agent
treatment
hiv
infect
bioisoster
pyrimidin
nucleosid
compon
nucleic
acid
thiadiazol
ring
impart
antivir
activ
studi
concern
antivir
activ
deriv
often
gave
compound
moder
lower
vitro
activ
refer
drug
relev
exampl
chiral
synthes
akhtar
et
al
acid
cyclodehydr
correspond
thiosemicarbazid
vitro
hiv
inhibitori
activ
use
human
tlymphocyt
cell
gave
moder
low
halfmaxim
effect
concentr
valu
comparison
efavirenz
valu
best
result
obtain
deriv
figur
moder
valu
thu
compound
show
strain
iiib
strain
rod
compound
show
low
valu
cytotox
concentr
compound
concentr
reduc
viabil
mockinfect
cell
name
valu
compound
compound
respect
result
low
select
index
si
si
deriv
show
lower
activ
within
rang
howev
chemic
modif
scaffold
might
lead
compound
enhanc
activ
nnrti
deriv
obtain
hamad
et
al
amino
acid
analog
screen
strain
iiib
strain
rod
activ
inhibit
virusinduc
cytopath
effect
human
cell
base
tetrazolium
bromid
mtt
assay
n
phenylamino
methyl
acetamid
show
vitro
inhibitori
activ
valu
strain
iiib
strain
rod
respect
low
select
si
relationship
sar
studi
suggest
substitut
acetamid
moieti
thiadiazol
ring
may
lead
activ
deriv
compar
compound
bear
differ
heterocycl
ring
even
though
antihiv
activ
select
deriv
limit
compar
efavirenz
valu
si
may
serv
basi
futur
modif
search
new
potent
nonnucleosid
antivir
agent
new
class
nnrti
identifi
last
year
studi
crystallin
structur
rtnnrti
complex
suggest
nnrti
common
mode
action
interact
hydrophob
pocket
adopt
butterflylik
conform
arylthio
moieti
phenyl
ring
mimic
butterfli
wing
sar
studi
show
arylthio
moieti
strongli
influenc
antivir
activ
lead
differ
result
depend
stericelectron
properti
group
base
find
xiaoh
et
al
synthes
n
aryl
acetamid
deriv
new
nnrti
although
exhibit
less
activ
compar
standard
drug
zidovudin
halfmaxim
inhibitori
concentr
compound
show
signific
activ
micromolar
concentr
within
rang
tabl
observ
moieti
may
good
group
activ
provid
promis
antivir
agent
moreov
electron
properti
naryl
group
influenc
antivir
potenc
introduct
electronwithdraw
group
fluorin
trifluoromethyl
phenyl
ring
deriv
enhanc
antivir
activ
compar
unsubstitut
phenyl
deriv
sar
studi
suggest
stericelectron
properti
nphenyl
substitu
influenc
antiretrovir
activ
posit
addit
natur
naryl
ring
influenc
antivir
potenc
observ
deriv
pyrimidyl
ring
activ
compound
figur
molecular
model
studi
pyrimidyl
deriv
show
format
two
potenti
intermolecular
hydrogen
bond
involv
nitrogen
atom
amino
group
thiadiazol
ring
aminoacid
nnb
rt
addit
electrondefici
pyrimidin
ring
ligand
establish
interact
electronrich
benzen
ring
rt
despit
dock
simul
result
inhibitori
activ
compound
strain
iiib
replic
cell
cultur
lower
zidovudin
howev
given
butterflylik
orient
necessari
structur
condit
antiretrovir
activ
result
reveal
promis
inhibitori
potenti
scaffold
seri
deriv
synthes
intramolecular
cycliz
correspond
hydrazinecarbothioamid
acid
condit
activ
test
cell
mtt
assay
use
efavirenz
standard
drug
except
deriv
show
low
activ
valu
activ
compound
even
lower
valu
prove
substitut
halogen
halogenoalkyl
group
andor
phenyl
ring
led
decreas
loss
activ
figur
although
pyridin
deriv
exhibit
select
activ
fact
compound
show
antivir
activ
may
encourag
research
structur
subsequ
chemic
modif
substitut
aromat
ring
differ
group
may
lead
compound
improv
activ
invas
central
nervou
system
cn
viru
frequent
caus
brain
inflamm
progress
neurolog
diseas
commonli
refer
hiv
associ
neurocognit
disord
hand
hand
affect
aid
patient
character
neuron
dysfunct
includ
synapt
damag
neuron
degener
cell
dropout
cell
involv
hand
pathogenesi
macrophag
microglia
main
target
infect
brain
infect
macrophag
microglia
increas
product
releas
sever
solubl
neurotox
factor
glutam
induc
neuron
damag
glutamin
abund
amino
acid
human
bodi
involv
metabol
process
amino
acid
glutamin
produc
glutam
ammonia
enzym
glutamin
synthetas
convers
glutamin
glutam
catalyz
mitochondri
enzym
glutaminas
glutamineglutam
cycl
human
bodi
play
sever
import
metabol
function
thu
glutamin
glutam
precursor
biosynthesi
protein
neurotransmitt
nucleotid
nucleic
acid
import
biolog
molecul
glutamineglutam
cycl
substrat
synthesi
urea
liver
genesi
ammonia
kidney
hepat
renal
gluconeogenesi
glutamineglutam
exchang
regul
acidbas
balanc
kidney
act
oxid
fuel
intestin
cell
immun
system
provid
transport
nitrogen
organ
exist
glutamineglutam
cycl
cn
confirm
last
year
phosphateactiv
mitochondri
glutaminas
predomin
enzym
use
glutamin
brain
glutamin
present
extracellular
fluid
brain
high
concentr
provid
abund
substrat
glutaminas
therefor
hypothes
mitochondri
glutaminas
activ
respons
high
level
glutam
brain
infect
patient
glutam
mediat
differ
physiolog
process
elev
extracellular
concentr
glutam
induc
neuron
damag
eg
dementia
brain
atrophi
glutaminas
inhibitor
eg
etc
studi
vitro
abil
prevent
gener
glutam
infect
macrophag
result
support
hypothesi
glutaminas
mediat
glutam
gener
hivinfect
human
macrophag
glutaminas
inhibit
variou
inhibitor
hivinduc
glutam
product
decreas
neuron
damag
diminish
furthermor
glutaminas
inhibitor
noncompetit
mechan
inhibit
describ
find
support
glutaminas
potenti
compon
hand
process
provid
new
therapeut
target
treatment
neurocognit
disord
associ
hiv
infect
connect
result
larg
number
glutaminas
inhibitor
bisthiadiazol
pyridazinethiadiazol
skeleton
figur
respect
synthes
method
treat
prevent
multipl
viral
infect
includ
infect
retrovirus
multipl
experi
perform
order
studi
biolog
profil
compound
synthes
deriv
prodrug
physiolog
condit
vivo
convert
therapeut
activ
parent
compound
studi
also
conduct
obtain
pharmaceut
prepar
suitabl
use
human
patient
compris
synthes
deriv
one
pharmaceut
accept
excipi
addit
author
assum
deriv
may
use
alon
combin
known
antivir
drug
studi
kidneytyp
glutaminas
inhibit
show
good
result
mani
deriv
compound
valu
deuterium
deriv
valu
human
cytomegaloviru
hcmv
herpesvirida
famili
ubiquit
deoxyribonucl
acid
viru
infect
peopl
age
hcmv
infect
acquir
horizont
vertic
transmiss
hcmv
spread
infect
peopl
direct
contact
bodi
fluid
carri
viru
urin
saliva
cervicovagin
secret
sperm
breast
milk
vertic
transmiss
organ
transplant
mother
child
transmiss
via
blood
transfus
also
possibl
blood
test
indic
adult
popul
experienc
hcmv
infect
time
life
although
infect
asymptomat
certain
patient
group
babi
infect
birth
children
adult
weaken
immun
system
due
diseas
medic
eg
hivinfect
patient
organ
transplant
recipi
develop
sever
ill
requir
medic
treatment
hcmv
abl
remain
latent
sever
cell
human
bodi
long
time
reactiv
person
develop
immun
system
suppress
firstlin
drug
recommend
treatment
hcmv
infect
intraven
ganciclovir
oral
administ
valganciclovir
although
toler
ganciclovir
valganciclovir
accept
hematolog
neurolog
side
effect
occur
neutropenia
thrombocytopenia
anemia
main
toxic
effect
limit
therapi
drug
serum
creatinin
level
may
increas
ganciclovir
therapi
requir
monitor
renal
function
encephalopathi
neurotox
effect
ganciclovir
valganciclovir
foscarnet
also
effect
antihcmv
drug
cidofovir
broadspectrum
antivir
good
activ
hcmv
drug
caus
high
level
nephrotox
limit
treatment
novel
deriv
antivir
activ
hcmv
patent
larg
number
synthes
compound
test
hcmv
polymeras
assay
concentr
degre
enzym
inhibit
rang
among
activ
compound
four
deriv
exhibit
inhibit
rate
deriv
show
inhibit
rate
deriv
show
inhibit
rate
three
structur
seri
stand
among
activ
deriv
deriv
deriv
deriv
tabl
tabl
tabl
deriv
belong
seri
time
activ
compound
belong
seri
conclud
moieti
good
scaffold
antihcmv
activ
compound
also
show
good
inhibitori
activ
deriv
contain
five
sixmemb
satur
heterocycl
moieti
imidazolidinyl
tetrahydrofuryl
piperidinyl
morpholinyl
thiomorpholinyl
aromat
unsatur
heterocycl
moieti
furyl
pyrrolyl
pyridyl
benzothiazolyl
etc
eg
deriv
synthes
deriv
shown
inhibitori
activ
hcmv
polymeras
antivir
activ
limit
specif
mechan
action
compound
may
activ
cytomegaloviru
hcmv
polymeras
inhibit
mechan
action
addit
experi
mani
compound
also
show
activ
herp
virus
varicellazost
viru
vzv
viru
ebv
herp
simplex
viru
hsv
human
herpesviru
type
pharmaceut
composit
contain
compound
pharmaceut
accept
salt
use
antivir
agent
also
studi
studi
conduct
administr
pharmaceut
prepar
parenter
topic
oral
rectal
rout
depend
purpos
use
treat
intern
extern
viral
infect
acut
respiratori
infect
major
global
health
problem
respons
million
death
worldwid
year
infect
top
five
caus
mortal
worldwid
lead
caus
mortal
among
children
five
year
age
mani
develop
countri
acut
respiratori
infect
often
caus
virus
viral
serotyp
associ
human
respiratori
diseas
includ
influenza
influenza
b
viru
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
human
adenoviru
hadv
human
coronaviru
hcov
human
rhinoviru
hrv
human
metapneumoviru
hmpv
human
bocaviru
hbov
addit
two
human
polyomavirus
hpyv
kipyv
wupyv
detect
patient
respiratori
infect
infect
affect
age
group
nearli
sever
episod
occur
children
five
year
elderli
immunocompromis
individu
eg
hivinfect
patient
adult
viral
respiratori
infect
caus
pneumonia
case
asthma
complic
chronic
obstruct
pulmonari
diseas
exacerb
consequ
common
viral
respiratori
infect
caus
greater
econom
burden
mani
clinic
condit
term
medic
expens
product
loss
world
health
organ
support
monitor
acut
respiratori
diseas
worldwid
sinc
influenza
viru
belong
orthomyxovirida
famili
caus
respiratori
infect
global
popul
everi
year
flu
pandem
caus
influenza
subtyp
kill
million
peopl
around
world
asian
influenza
caus
influenza
subtyp
occur
hong
kong
influenza
caus
influenza
subtyp
took
place
made
far
fewer
victim
spanish
flu
peopl
die
asia
due
strain
avian
flu
flu
pandem
swine
flu
second
pandem
involv
strain
influenza
viru
classifi
influenza
genet
materi
origin
three
differ
speci
human
avian
swine
chemotherapi
prophylaxi
influenza
infect
compris
agent
block
influenza
viru
protonselect
ion
channel
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
laninamivir
peramivir
class
induc
viru
resist
therefor
urgent
need
develop
new
antivir
agent
novel
mechan
action
altern
concept
recent
emerg
base
idea
design
new
molecul
target
host
cell
factor
hijack
viru
replic
hosttarget
antivir
altern
strategi
address
host
structur
involv
viru
life
cycl
type
inhibitor
could
exhibit
significantli
greater
barrier
select
drugresist
virus
addit
display
broadspectrum
antivir
activ
interact
cellular
target
common
sever
virus
host
factordirect
antivir
therapi
recent
studi
increasingli
recogn
relev
approach
combat
viral
resist
provid
broadspectrum
antivir
agent
mani
studi
current
develop
find
new
influenza
inhibitor
tatar
et
al
synthes
deriv
antivir
activ
respiratori
virus
influenza
influenza
influenza
b
rsv
felin
coronaviru
investig
result
summar
tabl
activ
observ
highest
concentr
test
subtox
concentr
influenza
b
rsv
vitro
antivir
assay
show
n
methylthio
phenylamino
propyl
benzamid
influenza
viru
subtyp
inhibitor
valu
deriv
potent
among
test
compound
moder
activ
compar
standard
drug
oseltamivir
promis
scaffold
futur
develop
deriv
exhibit
activ
probabl
thiourea
moieti
favor
antivir
activ
strain
figur
viral
hepat
liver
inflamm
respons
death
everi
year
european
region
patient
may
acut
form
recent
infect
rel
rapid
onset
chronic
form
five
main
hepat
virus
hav
hbv
hcv
hdv
hev
differ
way
transmiss
differ
impact
human
health
hav
hev
infect
usual
mild
peopl
recov
quickli
complet
infect
hbv
hcv
hdv
often
lead
chronic
infect
progress
liver
damag
develop
cirrhosi
liver
cancer
million
peopl
live
chronic
hbv
infect
million
hcv
infect
european
region
safe
effect
vaccin
prevent
hbv
infect
avail
sinc
vaccin
also
provid
protect
hdv
infect
unfortun
hcv
vaccin
yet
develop
mani
patient
infect
hbv
adult
born
hepat
b
vaccin
becam
avail
case
drug
treatment
option
sever
nucleosid
nonnucleosid
deriv
antihbv
eg
adefovir
entecavir
lamivudin
telbivudin
tenofovir
antihcv
activ
eg
boceprevir
grazoprevir
elbasvir
ledipasvir
sofosbuvir
telaprevir
use
chronic
infect
hbv
hcv
current
control
even
cure
due
cost
antivir
drug
chronic
hepat
access
treatment
major
obstacl
mani
countri
find
new
less
expens
antivir
drug
necess
phenylamino
methyl
prepar
correspond
phehylthiosemicarbazid
cycliz
sulfur
acid
deriv
test
antivir
activ
hepat
b
viru
hbv
use
cell
line
human
hepatoblastoma
cell
line
produc
hbv
viral
particl
cytotox
also
test
cell
viabil
method
mtt
assay
preliminari
screen
indic
high
inhibitori
activ
hbv
valu
low
cytotox
valu
select
index
si
compar
standard
drug
lamivudin
valu
result
conclud
may
good
substitu
ring
two
moieti
togeth
make
promis
scaffold
promot
antihbv
activ
sindbi
fever
less
common
human
viral
diseas
caus
mosquitoborn
viru
call
sindbi
viru
togavirida
famili
despit
wide
distribut
sindbi
viru
symptomat
infect
human
report
limit
geograph
area
northern
europ
finland
sweden
russia
south
africa
australia
china
deriv
test
antivir
activ
sever
virus
deriv
methyl
allyl
show
antivir
activ
herp
simplex
tkko
herp
simplex
tkko
acv
sindbi
viru
coxsacki
viru
punto
toro
viru
concentr
highest
antivir
activ
exhibit
sindbi
viru
deriv
concentr
seem
size
amino
group
substitu
influenc
antivir
activ
deriv
small
alkyl
group
show
antivir
activ
compound
bulki
aromat
cycloalkyl
group
capabl
viral
inhibit
figur
deriv
also
screen
herp
simplex
herp
simplex
tkko
acv
sindbi
viru
coxsacki
viru
punto
toro
viru
tabl
amid
amin
exhibit
antivir
activ
subtox
concentr
vitro
test
show
antivir
activ
thiourea
deriv
highlight
studi
report
deriv
bear
nhcsnh
group
demonstr
antivir
activ
deriv
exhibit
activ
differ
strain
hsv
deriv
show
activ
sindbi
viru
coxsacki
viru
punto
toro
viru
figur
reduc
replic
dna
virus
adenoviru
herp
simplex
rna
virus
polioviru
echoviru
coxsacki
viru
concentr
rang
vitro
experi
perform
use
sampl
human
aneuploid
cell
infect
infecti
unit
per
cell
deriv
highli
activ
viral
strain
significantli
reduc
viral
replic
concentr
best
inhibit
record
echoviru
virion
complet
inhibit
concentr
tabl
regard
mechan
action
author
assum
compound
may
act
viral
structur
protein
prevent
assembl
viru
particl
deriv
compound
prepar
methyl
deriv
allyl
deriv
reduc
replic
rna
virus
polioviru
coxsacki
viru
concentr
ethyl
deriv
complet
inact
viral
strain
tabl
result
suggest
import
side
chain
antivir
activ
figur
cui
et
al
synthes
sever
gener
formula
figur
compound
show
antivir
activ
virus
flavivirida
famili
west
nile
viru
dengu
viru
use
nonnucleosid
deriv
antivir
chemotherapeut
agent
stimul
extens
research
synthesi
compound
class
howev
mani
antivir
drug
nucleosid
analog
act
suppress
synthesi
viral
dna
rna
lead
inhibit
viru
replic
cell
divis
research
carri
find
new
nucleosid
antivir
agent
natur
nucleobas
replac
heterocycl
ring
seen
deriv
antivir
activ
evalu
vitro
viral
strain
parasit
chenopodium
amaranticolor
abil
deriv
control
viral
infect
chenopodium
amaranticolor
leav
studi
two
concentr
ppm
ppm
gener
compound
show
good
rate
viral
infect
control
ppm
best
result
observ
deriv
bear
dxylobutyl
group
compound
control
deriv
control
substitu
aryl
ring
significantli
influenc
biolog
activ
although
compound
methoxi
group
slightli
activ
deriv
bear
methyl
group
tabl
figur
studi
may
use
obtain
new
pesticid
agricultur
research
focus
deriv
indic
broad
spectrum
pharmacolog
activ
associ
good
physicochem
pharmacokinet
properti
articl
present
literatur
review
deriv
evalu
antivir
activ
sever
viral
strain
addit
moieti
antivir
activ
also
depend
natur
substitu
studi
shown
effici
substitu
antivir
activ
class
base
literatur
data
scaffold
may
consid
possibl
pharmacophor
group
incorpor
structur
known
compound
enhanc
antivir
activ
contribut
search
develop
new
medicin
altern
treatment
viral
infect
